PET Scan Study for Neurodegenerative Diseases
Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases
- Age
- 50 – 85
- Sex
- Any
- Trial phase
- Phase 4
- Study type
- Interventional
- Purpose
- Basic Science
- Participants needed
- 75 (estimated)
- Sponsor
- Vanderbilt University Medical Center · Other
This trial is looking for patients with certain neurodegenerative diseases to compare with healthy individuals. Participants will undergo a PET scan to measure brain receptors related to their condition.
You may be able to join if
- I have been diagnosed with Parkinson disease or another listed condition.
- I have psychosis that started after my Parkinson's disease diagnosis.
- I have a study partner who can accompany me to visits.
- I am matched in age and gender with the healthy participants.
You may not be able to join if
- I have had a stroke or other serious medical issues.
- I cannot tolerate an MRI scan.
- I have taken serotonergic medications in the last 6 weeks.
- I cannot give my own consent.
- I am pregnant or breastfeeding.
- I have psychosis due to other medical or psychiatric issues.
- I have used pimavanserin before.
- I have taken antipsychotics in the last 2 weeks.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your EligibilityIt is hypothesize that patients with clinically diagnosed neurodegenerative diseases will have significantly different receptor occupancy of 5HT2A receptors compared to a healthy age/sex-matched control group. This will be tested by measuring 5HT2A receptor density using the PET radioligand (R)-\[18F\]MH.MZ in both populations.
Loading trial locations…